More than 150 people gathered for a formal investiture ceremony honoring the University of Vermont’s newest endowed faculty members and recognizing the donors who made the positions possible on August 21, 2018 at the UVM Alumni House. Michael LaMantia, M.D., M.P.H., was invested as the inaugural Holly and Bob Miller Chair in Memory and Aging and Rosemary Dale, Ed.D., A.P.R.N., was invested as the first Holly and Bob Miller Professor in Nursing Leadership.

On Thursday, August 16, the National Institute of Allergy and Infectious Diseases (NIAID) announced that vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine.

Kathryn Huggett, Ph.D., director of the Teaching Academy at the Larner College of Medicine at the University of Vermont, has announced the names of 16 new members of the Teaching Academy.

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, Md., and at the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont in Burlington.